Rapport Therapeutics (RAPP) Profit After Tax (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Profit After Tax for 4 consecutive years, with -$19.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 4760.42% year-over-year to -$19.9 million; the TTM figure through Mar 2026 stood at -$107.3 million (down 571.67% YoY), while the FY2025 annual figure was -$111.5 million, down 21097.72% from the prior year.
• Profit After Tax rose to -$19.9 million in Q1 2026 per RAPP's latest filing, from -$33.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $57.4 million in Q4 2024 and bottomed at -$33.8 million in Q4 2025.
• Historically, Profit After Tax has averaged -$11.3 million across 4 years, with a median of -$17.5 million in 2024.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 524.62% — and 2026, when it sank 4760.42%.
• Rapport Therapeutics' Profit After Tax stood at -$13.5 million in 2023, then jumped by 524.62% to $57.4 million in 2024, then slumped by 158.85% to -$33.8 million in 2025, then soared by 41.09% to -$19.9 million in 2026.
• Business Quant data shows RAPP's Profit After Tax at -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.